More News! 27 Aug 2025 Zemcelpro, the first blood cord expansion therapy to reach the EU market Find out about ExCellThera’s zemcelpro, the first blood cord expansion therapy to reach the European market, and only the second globally. August 27, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 21 Feb 2025 The future of organ transplants: Xenotransplantation, 3D bioprinting and stem cells Discover how biotech could solve the organ shortage crisis through xenotransplantation, 3D bioprinting and stem cells. February 21, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2024 Spinal cord injury: Are we getting closer to a treatment? Delve into the spinal cord injury treatment landscape with a few pharmaceutical approaches that could tackle this complex condition. October 7, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 5 Oct 2023 Saving lives with xenotransplantation: how biotechs are solving the transplant shortage crisis On January 7, 2022, a surgery was performed on David Bennett to give him a new heart. But this was no ordinary transplant surgery. Instead of receiving a heart from a human donor, the 57-year-old, who did not qualify for a traditional transplant, received a pig heart. This surgery marked a historic breakthrough, becoming the […] October 5, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 14 Jul 2023Beyond Biotech podcast 54 1:24 Labiotech news3:45 TolerogenixX This week, we have a conversation with Matthias Schaier, CEO of TolerogenixX, about tackling rejection of organs following transplantation. TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant […] July 14, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 TolerogenixX expands trial and closes €12M financing TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […] July 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 30 Jun 2023 Virus tracking could be key to kidney transplant patients’ drug choices By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […] June 30, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 3 Aug 2022 Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers US-based Orca Bio, today announced Precision-T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bio’s lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic […] August 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Treatment for highly-sensitized kidney transplant patients approved and recommended Treatment offered by Hansa Biopharma for the densensitization of highly sensitized adults prior to kidney transplants from deceased donors has been recommended by the UK’s National Institute for Health and Care Excellence (NICE). NICE considers Idefirix (imlifidase), made by Hansa, a Swedish company that specializes in enzyme technology for rare immunological conditions, to be a […] June 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 Synklino raises €29.8M to trial cytomegalovirus drug Danish biotech Synklino has completed a Series A fundraising round that netted €29.8M ($31.8M). The company is developing drugs for the treatment of chronic viral infections, and the funding will be used for its drug candidate, SYN002, for the treatment of cytomegalovirus (CMV). This will involve both ex vivo and in vivo Phase 1 clinical […] June 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email